Evidence map›Paper›PMID 41511325›Full record

ReviewCells2025

Colon Organoids as Experimental Models to Study the Effect of Micro-Nanoparticles as a Driver of Early-Onset Colon Cancer.

Zahra Heydari, Gobinda Sarkar, Lauren Helgeson, Estela Mariel Cruz Garcia, Alexandra Ros, Khashayarsha Khazaie, Lisa Boardman

Abstract readReview
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zahra HeydariDepartment of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
Gobinda SarkarDepartment of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
Lauren HelgesonDepartment of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
Estela Mariel Cruz GarciaSchool of Medicine, University of Puerto Rico, San Juan, PR 00921, USA.ORCID 0009-0009-2013-5256
Alexandra RosThe Biodesign Institute, Arizona State University, Tempe, AZ 85281, USA.
Khashayarsha KhazaieDepartment of Immunology, Mayo Clinic, Scottsdale, AZ 85259, USA.ORCID 0000-0002-7884-1817
Lisa BoardmanDepartment of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.

Funding

PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI GREGORY J. GORES · 2009 to 2026
$22.2M
C-SiG Core(s): Epigenomics & Spatial Biology Core, and Clinical Core of the Mayo Clinic Center for Cell Signaling in Gastroenterology P30DK084567Curtiss Fund 92541775NIDDK NIH HHS P30 DK084567
6 · The paper itself

Abstract

Early-onset colorectal cancer (EOCRC) in people < 50 years of age has been rising globally, yet its causes remain unknown. Emerging evidence suggests that environmental factors, including exposure to micro-and nanoplastics (MNPs), may contribute to colorectal carcinogenesis. MNPs can enter the gastrointestinal tract through ingestion, translocate across the epithelial barrier via endocytosis or paracellular pathways, and interact directly with epithelial and immune cells. Once internalized, they may generate events associated with tumor initiation including oxidative stress, disruption of membrane integrity, pro-inflammatory signaling, and disruption of genomic and epigenomic stability. Patient-derived colorectal organoids offer a physiologically relevant and scalable 3D model that closely mimics the cellular architecture and genetic landscape of primary tumors. We highlight how organoid models can be leveraged to study the impact of MNPs on the key processes of inflammation, DNA damage, senescence, and epigenetic modifications. Furthermore, we discuss the application of organoid-based systems to model EOCRC driven by environmental exposures, including the integration of organoid platforms with high-throughput assays, omics profiling, and microfluidics to better capture MNP-induced pathogenic mechanisms. Altogether, colorectal organoids provide a powerful bridge between environmental plastic exposure and EOCRC etiology, offering a tractable platform to identify mechanistic pathways and potential biomarkers of early disease.

Indexed as

ColonColonic NeoplasmsModels, BiologicalNanoparticlesOrganoidsAnimalsHumanscolorectal cancerearly-onset CRCmicro- and nanoplasticsorganoid

Identifiers

PMID41511325
PMCPMC12786032

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.